Natalizumab induces and maintains continuous response and remission in patients with active Crohn's disease despite prior anti-tumor necrosis factor-alpha treatment

R Panaccione, J Colombel, R Enns, B Feagan, S Hanauer, Ian Lawrance, P Rutgeerts, W Sandborn, S Schreiber, S Targan, S Van Deventer

    Research output: Chapter in Book/Conference paperConference paper

    Original languageEnglish
    Title of host publicationINFLAMMATORY BOWEL DISEASES
    PagesS10-S10
    Volume14
    Publication statusPublished - 2008
    EventNatalizumab induces and maintains continuous response and remission in patients with active Crohn's disease despite prior anti-tumor necrosis factor-alpha treatment -
    Duration: 1 Jan 2008 → …

    Conference

    ConferenceNatalizumab induces and maintains continuous response and remission in patients with active Crohn's disease despite prior anti-tumor necrosis factor-alpha treatment
    Period1/01/08 → …

    Cite this

    Panaccione, R., Colombel, J., Enns, R., Feagan, B., Hanauer, S., Lawrance, I., ... Van Deventer, S. (2008). Natalizumab induces and maintains continuous response and remission in patients with active Crohn's disease despite prior anti-tumor necrosis factor-alpha treatment. In INFLAMMATORY BOWEL DISEASES (Vol. 14, pp. S10-S10)
    Panaccione, R ; Colombel, J ; Enns, R ; Feagan, B ; Hanauer, S ; Lawrance, Ian ; Rutgeerts, P ; Sandborn, W ; Schreiber, S ; Targan, S ; Van Deventer, S. / Natalizumab induces and maintains continuous response and remission in patients with active Crohn's disease despite prior anti-tumor necrosis factor-alpha treatment. INFLAMMATORY BOWEL DISEASES. Vol. 14 2008. pp. S10-S10
    @inproceedings{a2519b2983a048c18feeb061a9e03bf2,
    title = "Natalizumab induces and maintains continuous response and remission in patients with active Crohn's disease despite prior anti-tumor necrosis factor-alpha treatment",
    author = "R Panaccione and J Colombel and R Enns and B Feagan and S Hanauer and Ian Lawrance and P Rutgeerts and W Sandborn and S Schreiber and S Targan and {Van Deventer}, S",
    year = "2008",
    language = "English",
    volume = "14",
    pages = "S10--S10",
    booktitle = "INFLAMMATORY BOWEL DISEASES",

    }

    Panaccione, R, Colombel, J, Enns, R, Feagan, B, Hanauer, S, Lawrance, I, Rutgeerts, P, Sandborn, W, Schreiber, S, Targan, S & Van Deventer, S 2008, Natalizumab induces and maintains continuous response and remission in patients with active Crohn's disease despite prior anti-tumor necrosis factor-alpha treatment. in INFLAMMATORY BOWEL DISEASES. vol. 14, pp. S10-S10, Natalizumab induces and maintains continuous response and remission in patients with active Crohn's disease despite prior anti-tumor necrosis factor-alpha treatment, 1/01/08.

    Natalizumab induces and maintains continuous response and remission in patients with active Crohn's disease despite prior anti-tumor necrosis factor-alpha treatment. / Panaccione, R; Colombel, J; Enns, R; Feagan, B; Hanauer, S; Lawrance, Ian; Rutgeerts, P; Sandborn, W; Schreiber, S; Targan, S; Van Deventer, S.

    INFLAMMATORY BOWEL DISEASES. Vol. 14 2008. p. S10-S10.

    Research output: Chapter in Book/Conference paperConference paper

    TY - GEN

    T1 - Natalizumab induces and maintains continuous response and remission in patients with active Crohn's disease despite prior anti-tumor necrosis factor-alpha treatment

    AU - Panaccione, R

    AU - Colombel, J

    AU - Enns, R

    AU - Feagan, B

    AU - Hanauer, S

    AU - Lawrance, Ian

    AU - Rutgeerts, P

    AU - Sandborn, W

    AU - Schreiber, S

    AU - Targan, S

    AU - Van Deventer, S

    PY - 2008

    Y1 - 2008

    M3 - Conference paper

    VL - 14

    SP - S10-S10

    BT - INFLAMMATORY BOWEL DISEASES

    ER -

    Panaccione R, Colombel J, Enns R, Feagan B, Hanauer S, Lawrance I et al. Natalizumab induces and maintains continuous response and remission in patients with active Crohn's disease despite prior anti-tumor necrosis factor-alpha treatment. In INFLAMMATORY BOWEL DISEASES. Vol. 14. 2008. p. S10-S10